Investor directory

Polaris Partners

Polaris Partners is a venture capital specializing in investments in all company lifecycle stages including earliest startup, seed, early stage, mid venture, late venture, first round investments, emerging growth, expansion, growth capital, liquidity, and minority growth equity investments. It typically invests in technology, energy, healthcare, life sciences, business services, and consumer sectors. Within technology the firm invests in seed, early stage, and growth equity, in the cloud infrastructure; SaaS; software; e-commerce; consumer Internet; data sciences, marketplaces, broadband telecommunication services, telecommunication software, communications Equipment distribution, network software, wireless networking equipment, communication equipment, and digital media and entertainment sectors. Within healthcare, it invests in seeding, early venture, and growth equity, in the biotech and pharmaceuticals; medical devices, diagnostics, medical device research equipment, therapeutic devices, drug delivery technologies, gene research and development, protein and genome sequence products, life sciences and tool service, healthcare services and products, digital healthcare; and healthcare IT sectors. Within consumer, the firm invests in early to seed, and growth equity in e-commerce, consumer services, media, entertainment services, food and beverages, and consumer technology sectors. The firm prefers to invest in portfolio companies based in North America with a focus the United States; Canada, Caribbean, Central America and Mexico and can selectively invest in Asia and Europe with a focus on Ireland. It typically invests between $0.5 million and $150 million in portfolio companies with a EBITDA between $4 million and $25 million. It takes minority and majority stakes in companies. The firm generally acts as a lead or co-lead investor. Polaris Partners was founded in 1996 and is based in Boston, Massachusetts with additional offices in Dublin, Ireland; San Francisco, California; and Waltham, Massachusetts.

Focus

Mid VentureSeries ATherapeuticsEarly VentureSeries BShow more
http://polarispartners.com
https://angel.co/company/polaris-partners-1
https://crunchbase.com/organization/polaris-partners
https://crunchbase.com/organization/polaris-partners-4f2f
https://facebook.com/404737049642094
https://linkedin.com/company/20197
https://linkedin.com/company/polaris-partners
https://signal.nfx.com/firms/polaris-partners
https://twitter.com/polarisvc
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=22471
https://www.privateequityinternational.com/database/#/profile?id=6643

Stephen D. Arnold

Founding Partner Emeritus

David Barrett

Managing General Partner

Dave Barrett

Partner

Marissa Bertorelli

Principal

Jack Burke

Associate

Alexandra Cantley

Partner

Darren Carroll

Partner

Brian Chee

Partner

Isaac Ciechanover

Partner

George Conrades

Venture Partner, Venture Partner Emeritus and Partner Emeritus

Alan L. Crane

Entrepreneur Partner

Jonathan A. Flint

Founding Partner

Jon Flint

Partner

Peter A. Flint

Venture Partner

Jason Franklyn

Associate

Harold Friedman

CFO

Brendan Hannigan

Entrepreneur Partner

Mark Jacobson

VP

Rahul Kakkar

Entrepreneur Partner

Timothy J. Kilgallon

CEO-in-Residence

Patrick Kinsel

Venture Partner

Dan Lombard

Partner

Ellie McGuire

Partner

Terry McGuire

Partner

Sabrina Chiasson Mclaughry

VP

Pat Mulach

Associate

Amir Nashat

Partner

Jeff Del Presto

VP

Connor Ryan

Senior Associate

Amy Schulman

Partner

Gary Swart

Partner

Sharif Vakili

Associate

Jim Weinstein

Entrepreneur Partner

Bryce Youngren

Partner

Joanna Zesiger

Director of Finance

727 past transactions

OM1

Series C in 2019
OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.

Pulmatrix

Series A in 2009
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.

Kallyope

Private Placement in 2018
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

Alector

Series C in 2015
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

CliQr Technologies

Series C in 2015
CliQr Technologies, Inc. develops a single platform for modeling, deploying, and managing applications across physical, virtual, and cloud environments. It offers CliQr CloudCenter, an application-defined management platform that provides infrastructure resources and deploys application components and data across datacenter, private, and public cloud environments. The also provides solutions for application migration, IT-as-a-Service, capacity augmentation, DevOps automation, and service providers. It offers its solutions through reseller partners worldwide. The company was founded in 2010 and is based in San Jose, California. As of April 15, 2016, CliQr Technologies, Inc. operates as a subsidiary of Insieme Networks, Inc.

Ultreo

Series C in 2007
Ultreo is a U.S.-based company that designs, develops, and manufactures power toothbrushes for consumers. The company combines patented ultrasound waveguide technology with sonic bristle action. It is headquartered in Redmond, Washington.

Soapstone Networks

Series A in 1997
Soapstone Networks (formerly Avici Systems) developer of Terabit Switch/Router technology aimed at providing the next generation of high performance, IP-based routers to carriers and Internet Service Providers worldwide. Soapstone Networks got liquidated in 2009 July.

Acusphere

Funding Round in 2003
Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

XTuit Pharmaceuticals

Series A in 2015
XTuit Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. It develops pharmaceutical preparations for use in the diagnosis and treatment of oncological, tumor, and inflammatory diseases. The company was incorporated in 2011 and is based in Waltham, Massachusetts.

EXOS

Venture Round in 2012
EXOS Physical Therapy and Sports Medicine, LLC provides athletic training and physical therapy services. The company was formerly known as D1 Sports Medicine, LLC and changed its name to EXOS Physical Therapy and Sports Medicine, LLC in August 2017. EXOS Physical Therapy and Sports Medicine, LLC was incorporated in 2010 and is based in Franklin, Tennessee. As of August 25, 2017, EXOS Physical Therapy and Sports Medicine, LLC operates as a subsidiary of Exos Partners, LLC.

InsideSales

Series C in 2014
XANT delivers the industry-leading sales engagement AI platform powered by Real DataTM. XANT provides solutions that accelerate revenue by enabling (sales) teams to build a better pipeline and close more deals. Our core differentiation stems from RealData that like modern AI apps such as WAZE, Netflix and Amazon use data though a collective that drives insights, scores and predictions across email, voice, LinkedIn, SMS interactions. Hundreds of customers across the globe including companies such as American Express, Cisco, John Hancock, and Pluralsight, trust XANT to drive productivity, visibility, and effectiveness in their prospect and customer interactions.

Ember

Venture Round in 2004
Ember is a design-led temperature control brand whose mission is to revolutionize the way people eat, drink and live. Founded by inventor and serial entrepreneur Clay Alexander, Ember designs and develops patented technology and products that disrupt industries across healthcare, wellness, consumer products and more. From inventing the world’s first temperature control smart mug, to revolutionizing the cold chain for temperature sensitive medicines, Ember is creating a multidisciplinary temperature control platform that brings precision temperature control to your fingertips.

Impinj

Series B in 2002
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.

Impinj

Venture Round in 2012
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.

Alector

Private Placement in 2018
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Advion Inc.

Series B in 2002
Advion is a global company that offers a variety of systems and consumables for life science research. Its clientele is comprised of pharmaceutical companies, government life science research agencies, and universities. Advion provides a diverse portfolio of microfluidic and mass spec-based products for the life science industry. It was founded in 1993. The company is headquartered in New York, United States.

Engine Biosciences

Series A in 2021
Engine Biosciences Pte. Ltd. develops a validated platform for drug discovering, developing combination therapeutics, and cellular reprogramming. The company's artificial intelligence and genetic perturbation platform allows researchers and drug developers to uncover the gene interactions and biological networks. It provides test therapies that specifically target genetic interactions, and make analyses and predictions for precision medicine applications. The platform provides drug discovery, such as target discovery, drug repositioning, repurposing, pathway, and massive online analysis (MoA) analysis. It caters to the American fortune 500 companies and research institutions. The company was founded in 2014 and is based in Singapore.

Baxter Planning

Corporate Round in 2017
Baxter pioneered the development of Web-based solutions to meet the unique demands of inventory planning across complex, global supply chains in the service parts, high tech and healthcare industries. Their software Prophet™, is a suite of integrated forecasting and planning applications that enables their clients to achieve industry-leading customer service levels while significantly controlling inventory and increasing profitability. Baxter also offers inventory planning consultation with an experienced team who can help you lower your inventory costs while improving your customer's satisfaction.

Wakonda Technologies

Series A in 2008
Wakonda Technologies was founded in 2005 by Dr. Les Fritzemeier and Professor Ryne Raffaelle of the Rochester Institute of Technology. The company was established to exploit the intersection of their respective skills in metallurgical processing and advanced photovoltaic devices. Wakonda was started in Rochester NY and used the facilities at RIT, Cornell University and several government agencies to conduct proof of concept experiments. In 2008, the company moved to Massachusetts to accelerate product development and early commercialization. Wakonda has received several honors over its short history, winning the first ever Golden Horseshoe Business Challenge in upstate NY and being named the National Renewable Energy Laboratory's Entrepreneur of the Year in 2007.

Athenix

Series D in 2008
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.

Iora Health

Private Placement in 2018
Iora Health, Inc. operates a healthcare system that provides primary care services in the United States. It operates primary care practice for college employees and their adult dependents. The company also provides educational offerings, including group visits to help patients stay on track with their health. Iora Health, Inc. was founded in 2010 and is based in Boston, Massachusetts.

Experience.com

Venture Round in 2009
Experience, Inc. started in 1996 to help young adults learn from the experiences of others. More than a bank of resumes or a traditional job board, they help people understand their interests and aptitudes, and how they can apply their talents in the workforce. Their community at its core empowers the next generation workforce to access a world of possibilities.

Nomad Health

Series D in 2021
Nomad Health, Inc. operates an online marketplace that enables users to find freelance and permanent clinical work in the United States. Its market place enables doctors to search for jobs by location, pay rate, medical facility, and more; and healthcare facilities to find doctors. The company was incorporated in 2015 and is based in New York, New York.

PacketLight

Series A in 2000
Established in 2000, PacketLight Networks offers a suite of Leading DWDM and CWDM solutions for optical fiber communication, for transport of data, storage, voice and video applications, over dark fiber and WDM networks, featuring high quality, reliability with layer-1 fiber encryption capabilties, ultimate performance and functionality at affordable prices. Their products are distinguished with low power consumption ideal for CLE (Customer Located Equipment) allowing maximum flexibility as well as ease of maintenance and operation and providing true Pay-as-you-grow architecture.

480 Biomedical

Series A in 2011
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Ironwood Pharmaceuticals

Venture Round in 2009
Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, engages in developing and marketing human medicines. It engages in developing a pipeline of clinical candidates in the areas of gastrointestinal diseases, cardiovascular diseases, pain, and inflammation. The company's operationally independent subsidiary, Microbia Inc., engages in developing and commercializing bioprocesses for use in pharmaceuticals, foods, and specialty and industrial chemicals. Ironwood Pharmaceuticals, Inc. was formerly known as Microbia, Inc. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Transoma Medical

Series C in 2007
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Montis Biosciences

Seed Round in 2020
Montis Biosciences develops immune-oncology therapeutics targeting the intersection between vascular dysfunction and immune suppression to treat solid tumors. It creates a target screening and assay platform to develop targets modulating interactions between tumor endothelial cells and perivascular macrophages. The company was founded in 2020 and is based in Meise, Belgium.

KenSci

Private Placement in 2019
KenSci's machine learning powered risk prediction platform helps healthcare providers and payers intervene early by identifying clinical, financial and operational risk to save costs and lives. KenSci's platform is engineered to ingest, transform and integrate healthcare data across clinical, claims, and patient-generated sources. With a library of pre-built models and modular solutions, KenSci's machine learning platform to integrates into existing workflows allowing health systems to better identify utilization, variation and improve hospital operations. With Explainable AI models for healthcare, KenSci is making risk-based prediction more efficient and accountable.

Akamai Technologies

Series B in 1999
Akamai is the provider of cloud services for helping enterprises provide secure, high-performing user experiences on any device, anywhere. If you've ever shopped online, downloaded music, watched a web video or connected to work remotely, you've probably used Akamai's cloud platform. Akamai helps enterprises accelerate innovation in the hyperconnected world by removing the complexities of technology so you can focus on driving your business faster forward. We enable enterprises to capitalize on market opportunities presented by trends like mobile and cloud while overcoming the challenges presented by security threats and the need to reach users globally. The Akamai Intelligent Platform™ reaches globally and delivers locally, providing unmatched reliability, security and visibility into your online business.

Africa Healthcare Network

Series A in 2019
Africa Healthcare Network (“AHN”) has established the first dialysis chain across Sub-Saharan Africa, providing high-quality, life-saving dialysis at affordable cost. AHN brings world-class technical expertise combined with developing world practical operating experience to a region in dire need of quality dialysis treatment. Dialysis is a life-saving treatment for patients with Acute Kidney Injury (AKI) and End-Stage Renal Disease (ESRD). The few hospitals that provide treatment operate centers that are slowly deteriorating while charging prohibitive prices. Additionally, the lack of trained professionals and limited capital investment in care for non-communicable diseases in Sub-Saharan Africa, dialysis centers are few and far between, causing patients to endure the high costs for travel to receive care. Those who cannot afford the costs of treatment and travel are resigned to death. Chronic Kidney Disease (CKD) and AKI are on the rise in the region due to strong epidemiologic factors, including increased urbanization leading to lifestyle diseases, other non-communicable diseases, HIV and other infections and toxins. Utilizing our network of executives/partners, we will secure high-quality equipment and train professionals to provide superior care. Our ability to source lowest cost consumables, operational efficiency and scale, will allow us to lower the cost to patients. The net result is increased access, higher quality and lower cost to patients, while maintaining profitability. AHN operates in Rwanda, Tanzania and Kenya.

amunix

Series A in 2020
Amunix Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops protein and peptide therapeutics products for cancer. It focuses on XTEN, a half-life extension platform; XPAT (XTENylated Protease-Activated T Cell Engager) platform using its XTEN technology to analyze protease activity in the tumor microenvironment; and Protease Triggered Immune Activator (ProTIA), an immuno-oncology therapeutic. The company caters to the academic, biotechnology, and pharmaceutical sectors. It has strategic partnerships with Janssen, Biogen-Idec, Noxxon, Baxalta, Ambrx, Seattle Genetics, and Versartis. The company was formerly known as Amunix, Inc. Amunix Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Mountain View, California.

Candesant Biomedical

Venture Round in 2019
Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis. It offers a technology that is based on the principle that alkali metals in contact with water generate energy. The insight was that when the amounts of metal and water are controlled, the result is targeted delivery of energy exactly at the site of the water. Its device is designed to target and inactivate the most active sweat glands. The company was founded in 2016 and is headquartered in San Francisco, California.

Transoma Medical

Series B in 2005
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Egnyte

Series D in 2013
In a content critical age, Egnyte fuels business growth by enabling content-rich business processes, while also providing organizations with visibility and control over their content assets. Egnyte’s cloud-native content services platform leverages the industry’s leading content intelligence engine to deliver a simple, secure, and vendor-neutral foundation for managing enterprise content across business applications and storage repositories. More than 16,000 companies trust Egnyte to enhance employee productivity, automate data management, and reduce file-sharing cost and complexity. Investors include Google Ventures, Kleiner Perkins, Caufield & Byers, and Goldman Sachs.

Biolex Therapeutics

Series C in 2007
Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

Adagio Therapeutics

Private Placement in 2020
Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Freenome

Private Placement in 2020
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

BridgePort Networks

Series C in 2006
Fixed-mobile convergence applications for telecommunications service providers

Earth Networks

Series B in 2004
Earth Networks, Inc. operates weather observation and lightning networks in the United States, Europe, and internationally. It gathers, analyzes, and distributes environmental observations from around the world to help promote a better understanding of the planet and its atmosphere. The company’s products and services include forecasting, LCD weather display, GIS data services, data feed, meteorological, online weather, plume modeling, lightning network, weather stations, dangerous thunderstorm alerts, weather monitoring and alerting, atmospheric data, and risk notification systems; and weather cameras. It serves various industries, such as agriculture, education, energy and utilities, media, sports and recreation, electric power, and transportation; and federal, state, and local emergency response and government agencies, clubs, societies, consumers, and organizations. The company was formerly known as AWS Convergence Technologies, Inc. and changed its name to Earth Networks, Inc. in January 2011. The company was founded in 1993 and is based in Germantown, Maryland.

Proficiency

Series C in 2001
Proficiency, Inc. provides product knowledge integration and CAD interoperability solutions that enable manufacturers and suppliers to share product knowledge from various engineering and manufacturing environments. Its solutions include product knowledge migration, which delivers a process of technology and methodology that meets migration needs; and supplier delivery solutions to original equipment manufacturers or higher tier suppliers. The company’s products also include Collaboration Gateway V7.0, which enables the transfer of the product knowledge between CAD systems that include geometry, features, sketches, manufacturing info, metadata, assembly information, and drawings in the conversion process; and Completion Wizard, which provides an interactive method of completing the process. In addition, it offers CAD translation services, such as geometry-only, product knowledge, and associative drawing translations; consulting services, such as migration strategy, supplier delivery strategy, and process integration consulting; and implementation services, such as training, customer support, and customer specific developments. The company serves various companies in the automotive, aerospace and defense, and heavy machinery industries. Proficiency, Inc. was founded in 1998 and is based in Marlborough, Massachusetts. As of July 1, 2009, Proficiency, Inc. operates as a subsidiary of ITI TranscenData.

Kronos Bio

Private Placement in 2019
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

Avitide

Series C in 2015
Avitide, Inc. discovers, manufactures, and supplies molecule-specific affinity purification solutions for the biopharmaceutical industry. It offers affinity separation technology that enables customers to achieve bioprocess development timelines, reduce program risk, predict commercial scalability, and reduce manufacturing costs. The company also develops affinity purification solutions for the manufacturing of life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Avitide, Inc. was incorporated in 2012 and is based in Lebanon, New Hampshire.

Iora Health

Private Placement in 2020
Iora Health, Inc. operates a healthcare system that provides primary care services in the United States. It operates primary care practice for college employees and their adult dependents. The company also provides educational offerings, including group visits to help patients stay on track with their health. Iora Health, Inc. was founded in 2010 and is based in Boston, Massachusetts.

Neumora Therapeutics

Series A in 2021
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

KSQ Therapeutics

Private Placement in 2018
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

Biolex Therapeutics

Series B in 2005
Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

Saegis Pharmaceuticals

Series B in 2003
Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders. The company has a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. It develops CNS therapeutics for patients facing memory loss and cognition deficits associated with aging, psychiatric disorders, and brain trauma. Saegis Pharmaceuticals was founded in 1999 and is based in Half Moon Bay, California.

Mesodyne

Pre Seed Round in 2020
Mesodyne's solution is a novel ultra-high energy density, multi-fuel, silent, compact power generator. Our generators convert fuel to electricity with heat and light as intermediaries: a small micro combustor heats a photonic crystal to incandescence and the resulting light is tailored to the bandgap of an infrared cell resulting in unprecedented high efficiencies.

Prospex Medical

Seed Round in 2005
Prospex Medical, now dormant, was a medical device incubator focused on innovating and incubating novel medical technologies. With an emphasis on regulated medical devices and non-regulated (quasi-consumer) medical products, Prospex Medical explored a wide variety of opportunities in the health care market. Through a process of market identification, clinical and technical research, physician collaboration, intellectual property generation, and proof of concept, Prospex Medical successfully created and spun-out two companies: BridgePoint Medical (www.bridgepointmedical.com) and Apnex Medical (www.apnexmedical.com).

Integrian

Series B in 2005
Integrian develops and manufactures mobile digital video solutions for the public safety.

Convoq

Series C in 2006
Convoq was founded to develop a more effective solution for collaborating in real time. The company's founder and management team are experienced software entrepreneurs and technologists with proven records for delivering innovative, secure, and scalable products. They have built companies and commercial products and have been successful in deploying applications and infrastructure to some of the world's leading institutions.

Amagma, Inc.

Series A in 2020
Amagma Therapeutics is a biotechnology company that specializes in the discovery and development of antibody therapeutics against inflammatory diseases. Its technology overactive extracellular proteases trigger tissue damage that can sustain broad inflammatory responses. The company was founded in 2019 and headquartered in Waltham, Massachusetts.

Pulmatrix

Series B in 2009
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.

CAMP4 Therapeutics

Series A in 2018
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.

Notarize

Series B in 2019
Notarize operates an online notary public service that enables users to connect with a commissioned online eNotary public by live video call. It offers Notarize, a software service that allows clients to complete the notarization process remotely and entirely online; Notarize for business, a platform for organizations and developers to collect notarized documents; and Notarize for Mortgage, a platform that digitizes the closing process with technology to coordinate lenders, title companies, and borrowers online. Notarize's electronic notary public service is offered to customers via iOS, Android and web Pat Kinsel founded the company as 16 Pins in May 2015. Notarize has its headquarters in Boston in Massachusetts.

Jibe

Series B in 2013
At Jibe, we create global recruiting software solutions to help the world’s leading companies identify, engage, and hire the best talent. Jibe's core technology is the Jibe Recruiting Cloud, a SaaS-based platform that enables leading companies to hire the best talent, regardless of their existing systems. Through this platform, Jibe provides a suite of products including personalized career sites and recruiting tools for sourcing, nurturing and marketing to candidates. Jibe currently serves the world's leading Fortune 500 companies, including Johnson & Johnson, FedEx, Marriott, and American Express. Elevated by strategic partnerships with Google and LinkedIn and backed by their expertise in recruiting technology, Jibe continues to be an innovative leader in the changing world of talent acquisition.

Pervasis Therapeutics

Seed Round in 2004
Pervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs.

Allux Medical

Venture Round in 2006
Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

Quantcast

Series C in 2010
Quantcast processes real-time data at the intersection of commerce and culture, providing useful, actionable insights for brands and publishers. Through Quantcast Measure, we have unlocked the data generated by more than 100 million digital destinations, helping publishers and creators understand and grow their businesses in ways never before possible. With Quantcast Advertise, adaptive modeling and intelligent machines are utilized to help thousands of marketers around the world find and interact with customers anywhere they connect to the digital world. Our more than 600 employees are driven by the potential for big data to radically improve everyone’s connected experiences and transform the way we all make sense of the world.

Egnyte

Series A in 2009
In a content critical age, Egnyte fuels business growth by enabling content-rich business processes, while also providing organizations with visibility and control over their content assets. Egnyte’s cloud-native content services platform leverages the industry’s leading content intelligence engine to deliver a simple, secure, and vendor-neutral foundation for managing enterprise content across business applications and storage repositories. More than 16,000 companies trust Egnyte to enhance employee productivity, automate data management, and reduce file-sharing cost and complexity. Investors include Google Ventures, Kleiner Perkins, Caufield & Byers, and Goldman Sachs.

SiCortex

Series A in 2004
SiCortex is the first company to engineer high-productivity computers from the silicon up. Instead of stacking large quantities of general computing chips together, they have carefully thought through the impact of every design element on the system, focusing attention on what truly drives performance.

Swiftly

Venture Round in 2017
Swiftly develops enterprise software that helps transit agencies and cities improve urban mobility. Built by transportation experts for transportation professionals, the Swiftly platform harnesses billions of data points and sophisticated algorithms to improve transit system performance, service reliability, and real-time passenger information. Swiftly’s technology platform is installed in over 50 cities from coast to coast, improving transportation services for millions of riders each day. Swiftly was founded on 2014 and is headquartered in San Francisco, California.

Heavy

Series E in 2006
Heavy is a platform for the most sought-after news and information. Through its flagship website, Heavy.com, and Spanish-language platform, AhoraMismo.com, readers benefit from rapid, unbiased reporting to access the content they want in real time. Heavy.com was founded by entrepreneurs Simon Assaad and David Carson in 1999 as a video-focused entertainment site aimed primarily at young men. It rebooted in 2012 as a news site and today receives nearly 25 million readers a month. Assaad continues to serve as CEO. Heavy’s content is driven by data around the stories, trends and products people search for the most. The editorial team is made up of a mix of veteran reporters with independent journalists, who work on an editorial agenda built for quality, efficiency and speed. Heavy’s rapid original reporting and user-friendly formats, such as its “5 Fast Facts” posts, offer facts about trending topics in real time. Heavy has also been recognized for reporting well ahead of mainstream news sites and is often sourced in editorial reporting. AhoraMismo is a Spanish-language platform that equips U.S. Hispanics with news, information and other resources to help them navigate daily life. From entertainment and sports news to educational content on health, wellness and women’s issues, to analysis of important issues such as immigration, politics and financial planning, AhoraMismo arms its readers with tools to be more informed and improve their quality of life.

Lyra Therapeutics

Series C in 2020
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.

Qstream

Series B in 2016
Qstream, Inc. develops a software as a service based mobile sales acceleration software for managing and measuring the human side of sales acceleration. It serves companies in technology, financial services, and life sciences sectors. Qstream, Inc. was formerly known as Spaced Education, Inc. The company was incorporated in 2008 and is based in Burlington, Massachusetts with engineering facilities in Dublin, Ireland; and Hood River, Oregon. It has a sales headquarters in Maidenhead, United Kingdom and an office in San Francisco.

Aepona

Series B in 2005
Aepona Ltd. provides application-led products and services to telecommunications operators worldwide. Its Universal Service Platform allows service creation and implementation to be carried out within the service network from underlying network resources. Aepona, Ltd. serves customers in Europe, North America, and South East Asia. The company was founded in 1999 and is headquartered in Belfast, United Kingdom. Aepona Ltd. is a former subsidiary of ApiON Ltd.

Adimab

Series B in 2008
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

OM1

Series D in 2021
OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.

Allurent

Series B in 2007
Allurent work on online shopping experiences that lead directly to competitive conversion rates and customer satisfaction.

Ocular Therapeutix

Series C in 2009
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Dewpoint Therapeutics

Private Placement in 2020
Dewpoint Therapeutics, Inc., a biotech company, engages in research of biomolecular condensates and cellular function to develop treatments for diseases like cancer, neurodegenerative disorders, immunology, cardiovascular, women’s health, and virology. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Ajax Health

Series C in 2019
Ajax Health is a Private equity and venture capital firm specializing in all stages of a company’s lifecycle. It seeks to invest in innovative medical device companies, medtech, healthcare services, digital health, biotechnology and healthcare IT that focus on truly innovative approaches to solving major issues in healthcare. Ajax Health was founded in 2017 and is based in Menlo Park, California with an additional office in New York City, New York.

PhyFlex Networks

Venture Round in 2004
PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Tausight

Private Placement in 2020
Tausight, Inc. develops a software for reducing healthcare cyber incidents of patient data theft. It serves chief information officer of health care sector. Tausight was founded in 2018 and is based in Sudbury, Massachusetts with additional office in San Francisco, California.

Cerulean Pharma

Venture Round in 2006
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.

Noema Pharma

Private Placement in 2020
Noema Pharma AG operates as a biotechnology company. The company develops therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. It develops and commercializes therapies for conditions affecting the nervous system, including Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. Noema Pharma AG was founded in 2019 and is based in Basel, Switzerland.

WHI Solution

Venture Round in 2000
WHI was founded as Wrenchead.com in March of 1999, to create a B2C ecommerce channel for traditional wholesalers. Word quickly spread from one satisfied user to another and by February of 2000 they had over 1 million visitors per month. During that time they also began to license their technology to enable wholesale distributors to do business online. That business began to grow dramatically and they knew they had to make a choice. They sold the B2C business to focus on providing better ebusiness solutions for distributors.

Quentis Therapeutics

Series A in 2018
Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases. The company's therapeutics are designed to target ER stress pathways and awaken the immune system's ability to fight cancer, enabling patients to get access to new treatments for cancer.

Imprivata

Series A in 2002
FairWarning’s platform helps healthcare and enterprise organizations comply with regulations, protect sensitive data, and prevent insider threats. A driving force in building the patient privacy monitoring industry, FairWarning expanded to support other highly regulated industries and applications like Salesforce to help customers easily interpret, investigate and detect anomalous user access or behavior. The company combines advanced technologies including machine learning and AI with best practices and managed services to provide the highest level of security to organizations across the globe. Safeguarding over 350 enterprise customers globally, including 35% of U.S. health systems, FairWarning is trusted to protect organizations’ sensitive data while creating a culture of privacy.

Centive

Venture Round in 2003
Centive focuses exclusively on delivering technology solutions for automating incentive compensation management. Centive's vision from the outset has been to help companies transform sales compensation management from a tactical commission calculation exercise into a strategic management tool for driving sales performance.

Zingdom Communications

Series C in 2006
Zingdom Communications went out of business. Zingdom Communications, Inc. provides SaaS integrated online meeting and live chat systems for sales, marketing, training, service, and support departments. It offers ASAP family, a flash-based suite with live chat and Web conferencing, including desktop sharing, powerpoint presentations, desktop control, VoIP audio, video, and record and playback.

OM1

Series B in 2018
OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.

Strata Health

Venture Round in 2014
Strata Health leverages technology to achieve dramatic patient flow improvement within health systems. Our clients say they’ve entrusted us with the job of creating patient flow solutions that achieve real and dramatic benefits for patients, their families and the world’s devoted front line caregivers. Operational in Canada and the UK, Strata Health is a privately held Canadian corporation. It is comprised of professionals with empathy for those who need care and intense respect for those who devote themselves to caring for others.

Selecta Biosciences

Series B in 2009
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.

Nanosys

Seed Round in 2001
Nanosys, Inc. develops and delivers quantum dot technology for high definition viewing experience for the display industry. It offers Quantum Dot Concentrate material; quantum dot nanomaterials; and Quantum Dot Enhancement film to industrial supply chain partners. Its products are used in tablets, televisions, smartphones, and other consumer electronics applications. Nanosys, Inc. was incorporated in 2001 and is based in Milpitas, California.

Neogene Therapeutics

Series A in 2020
Neogene Therapeutics, Inc. develops T cell therapies to treat cancer. The company was incorporated in 2018 and is headquartered in New York, New York.

Iora Health

Series F in 2020
Iora Health, Inc. operates a healthcare system that provides primary care services in the United States. It operates primary care practice for college employees and their adult dependents. The company also provides educational offerings, including group visits to help patients stay on track with their health. Iora Health, Inc. was founded in 2010 and is based in Boston, Massachusetts.

Automattic

Series B in 2008
Automattic is the company behind WordPress.com and WordPress.com VIP, the cloud version of WordPress. Automattic hosts and supports all WordPress.com sites ensuring that there is continuous and strategic development of the software available to its users. Automattic also supports WordPress.com VIP, a premium service designed for large-scale enterprises. WordPress.com VIP combines the benefits of WordPress.com and the ability to run custom code. In addition, WordPress.com VIP offers companies a robust CMS and 24/7 service.

FREEjit

Series A in 2010
FREEjit, Inc. is in Stealth mode. The company was incorporated in 2010 and is based in Newport Beach, California.

Incentive Systems

Series E in 2002
"Incentive Systems is the industry pioneer and leader in the Enterprise Incentive Management marketplace, which is predicted by AMR to grow rapidly, reaching an annual market size of $2 billion in software revenue alone in 2005, and is also the first software company in which Thomas Weisel Capital Partners, LP made a private equity investment," said Alan Menkes, partner, co-director of private equity for Thomas Weisel Partners LLC. "Since their initial investment, Incentive Systems has continued to deliver industry-leading technology and services to the marketplace, and has seen tremendous growth in demand for its solutions, among both public and private organizations, across several industries. The company is on track to reach its goal of profitability in the near-term, and they were delighted by the oppornity to lead this round and further strengthen their partnership with Incentive Systems."

Boxever

Series A in 2014
Boxever is the Customer Intelligence Cloud for marketers. It connects all of your customer, product and operational data, putting your customer at the center of your business and enabling true 1:1 personalization on a level you’ve never seen before. This results in lower acquisition costs, accelerated conversion rates, improved customer engagement and higher lifetime value. Using artificial intelligence, it acts as the “brain” within your CRM-tech ecosystem, taking in all data about the customer - including behavioural and transactional - deciding what should happen next and executing that action through the most appropriate channels - in real time, as it happens.

Egnyte

Series C in 2012
In a content critical age, Egnyte fuels business growth by enabling content-rich business processes, while also providing organizations with visibility and control over their content assets. Egnyte’s cloud-native content services platform leverages the industry’s leading content intelligence engine to deliver a simple, secure, and vendor-neutral foundation for managing enterprise content across business applications and storage repositories. More than 16,000 companies trust Egnyte to enhance employee productivity, automate data management, and reduce file-sharing cost and complexity. Investors include Google Ventures, Kleiner Perkins, Caufield & Byers, and Goldman Sachs.

Ocular Therapeutix

Series C in 2011
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Apnex Medical

Series C in 2012
Apnex Medical, Inc. manufactures and markets medical devices such as implants for the treatment of obstructive sleep apnea. Apnex Medical, Inc. was incorporated in 2006 and is based in Saint Paul, Minnesota.

B2Gnow

Venture Round in 2021
B2Gnow develops a turn-key, hosted software solution that streamlines and automates data-gathering, tracking, reporting, vendor management, and administrative processes. The result is a significant reduction in staff time and cost, allowing customers to focus on meeting their diversity goals. B2Gnow can save organizations 60%-80% of time spent on administrative and clerical activities while enhancing the impact and reach.

InsideSales

Series D in 2017
XANT delivers the industry-leading sales engagement AI platform powered by Real DataTM. XANT provides solutions that accelerate revenue by enabling (sales) teams to build a better pipeline and close more deals. Our core differentiation stems from RealData that like modern AI apps such as WAZE, Netflix and Amazon use data though a collective that drives insights, scores and predictions across email, voice, LinkedIn, SMS interactions. Hundreds of customers across the globe including companies such as American Express, Cisco, John Hancock, and Pluralsight, trust XANT to drive productivity, visibility, and effectiveness in their prospect and customer interactions.

Quartet Health

Series B in 2016
Quartet Health, Inc. develops and operates a cloud based platform that allows communication and collaboration between medical providers with behavioral health providers for patient care. Its platform works with health plans and health systems to provide actionable population insights and reports on behavioral health conditions to improve patient outcomes, as well as provides tools for patient self-management. The company was founded in 2014 and is based in New York, New York.